参芪散联合TP方案治疗晚期非小细胞肺癌患者的疗效及其对免疫功能的影响  

The Curative Effect of Shenqi Powder Combined with TP Scheme in Patients with Advanced Non-Small Cell Lung Cancer and Its Effect on Immune Function

作　　者：石织宏[1] 黄织春[1] 

机构地区：[1]内蒙古医科大学附属医院肿瘤内科,呼和浩特010050

出　　处：《世界中医药》2016年第11期2340-2343,2347,共5页World Chinese Medicine

基　　金：内蒙古自然科学基金项目(编号:2014MS0846);内蒙古医科大学附属医院重大研究项目(编号:NYFY ZD 2012001)

摘　　要：目的:研究参芪散联合TP方案治疗晚期非小细胞肺癌患者的疗效及其对患者免疫功能的影响。方法:选取本院2013年4月至2015年4月期间收治的80例晚期非小细胞肺癌的患者作为研究对象,采用单盲法将这80患者分为对照组和治疗组各40例。对照组晚期非小细胞肺癌患者采用TP方案进行化疗治疗,而治疗组在对患者进行TP方案化疗前2天使用参芪泻白散先进行治疗。治疗以28 d为1个周期,需连续治疗2个周期。最后观察对照组和治疗组2组患者的生活质量积分、免疫功能、中医证候积分、KPS评分以及不良反应等的变化情况。结果:对照组在治疗前后的生活质量评分比较没有统计学意义(t=0.461,P=0.646),治疗组在治疗前后的生活质量评分差异有统计学意义(t=-34.420,P<0.001);对照组在治疗前后的CD4^+细胞(t=2.210,P=0.030)以及CD4^+/CD8^+(t=2.846,P=0.006)都具有统计学意义,而仅仅只有CD8^+细胞在治疗前后没有统计学意义(t=1.608,P=0.112);治疗组在治疗前后的CD4^+细胞(t=-2.122,P=0.037)、CD8^+细胞(t=-2.393,P=0.019)以及CD4^+/CD8^+(t=-4.677,P<0.001)都具有统计学意义;而治疗后对照组和治疗组的CD4^+细胞(t=2.701,P=0.008)、CD8^+细胞(t=-2.805,P=0.006)以及CD4^+/CD8^+(t=-8.393,P<0.001)的比值都具有统计学意义;比较2组患者在化疗后的不良反应,对照组和治疗组在治疗后出现恶心呕吐的人数具有统计学意义(χ~2=8.584,P=0.003),出现周围神经感觉异常的人数也具有统计学意义(χ~2=6.270,P=0.012),都为治疗组较对照组显著减少。结论:对晚期非小细胞肺癌患者采用化疗治疗联合参芪泻白散治疗可以较好的在改善患者临床症状的同时减少患者的不良反应,并且提高患者的生存质量、免疫功能及延长患者的生存期。Objective：To analyze the curative effect of Shenqi Powder combined with TP scheme in advanced non -small cell lung cancer patients and its effect on immune function .Methods：Eighty cases of advanced non-small cell lung cancer patients were se-lected as the research objects and divide into control group and treatment group by single blind method （n=40）.Patients in con-trol group received TP chemotherapy treatment and patients in the treatment group received Shenqi Powder and TP scheme in ad -vanced non-small cell lung cancer patients .Results：The quality of life scores of the control group before and after the treatment showed no significant difference （t=0.461, P=0.461）.There was a significant difference of quality of life scores in the treat-ment group before and after the treatment （t=34.420, P〈0.001）.CD4 ＋cells and CD4 ＋/CD8 ＋（t=2.805, P=0.006） of the control group before and after treatment showed obviously significant differences , while CD8 ＋cells showed no difference （ t =1.608, P=0.019）.CD4 ＋cells （t=2.122, P=0.037）, CD8 ＋cells （t=2.393, P=0.019） and CD4 ＋/CD8 ＋of （t =-4.667, P〈0.001） of the treatment group after treatment indicated significant difference .CD4 ＋cells （t=2.701, P=0.008）, CD8 ＋cells （ t=2.805, P=0.006） and CD4＋/CD8 ＋between the control group and the treatment group after treatment indicated significant difference .The number of patients with nausea and vomiting after treatment showed significant difference between the control group and treatment group （χ2 =8.584, P=0.003） and the number of abnormal peripheral nervous sensation also showed significant difference （χ2 =6.270, P=0.012）.Conclusion：Shenqi Powder combined with TP scheme for patients with advanced non-small cell lung cancer may better relieve the patient′s clinical symptoms , improve quality of life , reduce adverse reactions , prolong survival and enhance the patient′s immune function .

关 键 词：参芪散 TP方案 晚期非小细胞肺癌 

分 类 号：R256.1[医药卫生—中医内科学] R273[医药卫生—中医学]